Palatin Technologies, Inc. (PTN)
| Market Cap | 95.06M |
| Revenue (ttm) | 259,445 |
| Net Income (ttm) | -36.77M |
| Shares Out | 231.34M |
| EPS (ttm) | -0.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,543,005 |
| Open | 0.425 |
| Previous Close | 0.414 |
| Day's Range | 0.410 - 0.433 |
| 52-Week Range | 0.330 - 1.300 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | 3.33 (+710.4%) |
| Earnings Date | Nov 15, 2021 |
About PTN
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a p...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for PTN stock is "Strong Buy." The 12-month stock price forecast is 3.33, which is an increase of 710.42% from the latest price.
News
Palatin to Present at H.C. Wainwright BioConnect Conference
CRANBURY, N.J., Jan. 7, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate...
Which Penny Stocks Are Investors Watching in 2022? 3 To Check Out
Add these three penny stocks to your January 2022 watchlist The post Which Penny Stocks Are Investors Watching in 2022? 3 To Check Out appeared first on Penny Stocks to Buy, Picks, News and Information ...
Palatin (PTN) Begins Phase III Study For Dry Eye Disease
Palatin (PTN) commences the pivotal phase III study evaluating PL9643 for the treatment of dry eye disease. Top-line data from the same is expected in the second half of 2022.
Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease
CRANBURY, N.J., Dec. 28, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulat...
4 Penny Stocks To Buy For Under $1 On Webull
Cheap penny stocks to watch this week. The post 4 Penny Stocks To Buy For Under $1 On Webull appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Top Penny Stocks To Watch Under $4 This Week
Are these on your penny stocks watch list this week? The post 3 Top Penny Stocks To Watch Under $4 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks To Buy For Under $1 & What To Watch Right Now
Looking for cheap penny stocks to buy? Here are 4 to watch trading below $1 right now.
Keep Your Eye On Palatin Technologies as $5 Price Target Gets Attention
With several high-conviction treatments in its pipeline, Palatin Technologies is delivering results -- and PTN stock may be ready to run soon. The post Keep Your Eye On Palatin Technologies as $5 Price ...
Here's Why Palatin Technologies, Inc. (PTN) Is a Great 'Buy the Bottom' Stock Now
Palatin Technologies, Inc. (PTN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreem...
Hot Biotech Penny Stocks to Buy Today? 3 For Your December Watchlist
Trading biotech penny stocks right now? Check these three out The post Hot Biotech Penny Stocks to Buy Today?
Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific Peptide
CRANBURY, N.J. , Nov. 30, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modula...
PTN Stock Alert: Why One Analyst Sees 1,371% Upside for Palatin Technologies
Palatin Technologies (PTN) stock is taking off on Wednesday thanks to an incredibly bullish new analyst price target for the shares. The post PTN Stock Alert: Why One Analyst Sees 1,371% Upside for Pala...
Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update
CRANBURY, N.J., Nov. 15, 2021 /PRNewswire/ -- Palatin Technologies, Inc., (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activ...
Palatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on November 15, 2021
CRANBURY, N.J., Nov. 10, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2022 operating results on Monday, November 15, 2021, before the...
Palatin Awarded "Top 10 Poster" Designation at the American Society of Retina Specialists (ASRS) 2021 Annual Meeting
CRANBURY, N.J., Oct. 22, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulat...
Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update
CRANBURY, N.J., Sept. 29, 2021 /PRNewswire/ -- Palatin Technologies, Inc., (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the acti...
Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 202...
CRANBURY, N.J., Sept. 27, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modula...
Palatin To Report Fourth Quarter And Fiscal Year End 2021 Results; Teleconference And Webcast To Be Held On September...
CRANBURY, N.J., Sept. 24, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2021 operating results on Wednesday, September 29, 202...
Palatin to Present Peptides Platform at the TIDES USA Conference
CRANBURY, N.J., Sept. 15, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modula...
Palatin to Participate in H.C. Wainwright 23rd Annual Global Investment Virtual Conference
CRANBURY, N.J., Sept. 13, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modula...
Palatin Announces Presentation at the Eyecelerator@ASCRS Conference
CRANBURY, N.J., July 22, 2021 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulat...
Palatin Announces Adjournment of Annual Meeting of Stockholders
CRANBURY, N.J., July 8, 2021 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) announced that its 2021 Annual Meeting of Stockholders that convened on June 8, 2021 and was adjo...
What Penny Stocks Investors Need to Know in July and 7 Stocks to Watch
What do you need to know about trading penny stocks in 2021? Here's 3 tips and 7 small-caps to watch The post What Penny Stocks Investors Need to Know in July and 7 Stocks to Watch appeared first on Pen...
Palatin Technologies Stock Moves Higher After Outlining Plans For Dry Eye Disease Treatment
Palatin Technologies Inc (NYSE: PTN) has completed an End-of-Phase 2 (EOP2) meeting with the FDA for PL9643 for the treatment of dry eye disease (DED). Palatin remains on track to initiate the Phase 3 p...